Use of Real-World Big Data to Assess the Effectiveness on Overall Survival Among Chemotherapy or Immunotherapy in First Line Metastatic Non-Small Cell Lung Carcinoma Patients in an Italian Setting in Value in Health
2022
ASL Vercelli
Tipo pubblicazione
Conference Abstract
Autori/Collaboratori (26)Vedi tutti...
Sangiorgi D
Clinica Otorinolaringoiatrica, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy
Degli Esposti L
Clinica Otorinolaringoiatrica, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy
Ancona DD
Clinica Otorinolaringoiatrica, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy
et alii...
Abstract
Objectives: The use of big data to assess the effectiveness of oncological treatments in clinical practice is gaining increasing interest. This analysis aimed to assess the overall survival of metastatic non-small cell lung (met-NSCLC) patients receiving chemotherapy (CT) or immunotherapy (I/O) as 1st line by using real-world data in a sample population in Italy. Methods: A retrospective observational analysis based on administrative data from a sample of Italian Local Health Units was conducted. Met-NSCLC patients starting a 1st line therapy with CT or I/O between 2017-2018 were identified. Stopping inclusion period up to 2018 enabled at least a two-years follow-up period for each included patient. Kaplan Meier overall survival analysis considered time (months) from therapy initiation to death. Multivariable analysis was performed to adjust for cofounders such as age, gender, metastasis, BRAF test prescription and pharmacological treatments. Results: A total of 3,126 (mean age±SD 68.6±9.8 years, 68.2% male) and 316 (mean age±SD 68.6±9.7 years, 74.4% male) patients initiated treatment with CT and I/O respectively. In both groups, the more frequent metastases detected were related to lymph nodes (42.1% CT, 24.1% I/O), bone (25.8% CT, 14.9% I/O) and brain (18.3% CT, 10.1% I/O). Median [95%CI] survival was 8.0 [7.4-8.6] and 14.6 [12.2-18.9] months for CT and I/O patients, respectively. Death was not reported in 31.2% of CT and in 44.3% of I/O cohorts. Multivariable analysis showed the risk of death to be significantly lower in patients treated with I/O compared to CT (HR [95%CI] 0.796 [0.681-0.930]). Conclusions: Results from our study showed among met-NSCL patients in 1stline a better overall survival of the I/O compared to CT patients and a reduced risk of death of I/O vs CT-treated patients. Our findings suggest real-world data could produce valuable insights into treatments and their outcomes in routine daily oncology practice, thus integrating the evide
DOI : 10.1016/j.jval.2021.11.012
Keywords
Italy; immunotherapy; human; health center; gender; follow up; controlled study; conference abstract; comparative effectiveness; cancer survival; female; cancer patient; brain; cancer chemotherapy; bone; adult; big data; endogenous compound; B Raf kinase; male; lymph node; overall survival; non small cell lung cancer; mortality; metastasis; retrospective study; prescription;